- Home
- BBU vs APLS Comparison
BBU vs APLS Comparison
Compare BBU & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBU | APLS |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BBU | APLS |
|---|---|---|
| Price | $30.64 | $18.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 20 |
| Target Price | ★ $39.40 | $31.89 |
| AVG Volume (30 Days) | 25.0K | ★ 1.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.81% | N/A |
| EPS Growth | N/A | ★ 112.50 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $1,003,782,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.97 |
| P/E Ratio | ★ N/A | $91.93 |
| Revenue Growth | N/A | ★ 28.46 |
| 52 Week Low | $18.63 | $16.10 |
| 52 Week High | $37.75 | $30.48 |
Technical Indicators
Market Signals| Indicator | BBU | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 29.79 | 28.28 |
| Support Level | $24.33 | $16.89 |
| Resistance Level | $36.93 | $20.42 |
| Average True Range (ATR) | 1.17 | 0.91 |
| MACD | -0.39 | -0.22 |
| Stochastic Oscillator | 0.81 | 4.91 |
Price Performance
Historical ComparisonAbout BBU Brookfield Business Partners L.P. Limited Partnership Units
Brookfield Business Partners LP is a business services and industrials company. It focused on operating businesses that are either low-cost producers and benefit from high barriers to entry. The company's operating segment includes Business services; Infrastructure services; Industrials and Corporate and other. It generates maximum revenue from the Business Services segment. Geographically operates in USA, Europe, Australia, Brazil, Canada, UK, Mexico and Other, majority of revenue is from UK.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.